全文获取类型
收费全文 | 60852篇 |
免费 | 6634篇 |
国内免费 | 2317篇 |
专业分类
耳鼻咽喉 | 131篇 |
儿科学 | 554篇 |
妇产科学 | 228篇 |
基础医学 | 2573篇 |
口腔科学 | 389篇 |
临床医学 | 5208篇 |
内科学 | 6795篇 |
皮肤病学 | 1062篇 |
神经病学 | 2066篇 |
特种医学 | 615篇 |
外国民族医学 | 7篇 |
外科学 | 1752篇 |
综合类 | 8038篇 |
现状与发展 | 5篇 |
一般理论 | 3篇 |
预防医学 | 3632篇 |
眼科学 | 650篇 |
药学 | 29230篇 |
26篇 | |
中国医学 | 3203篇 |
肿瘤学 | 3636篇 |
出版年
2024年 | 69篇 |
2023年 | 962篇 |
2022年 | 1173篇 |
2021年 | 2034篇 |
2020年 | 2218篇 |
2019年 | 2243篇 |
2018年 | 2276篇 |
2017年 | 2567篇 |
2016年 | 2398篇 |
2015年 | 2383篇 |
2014年 | 4050篇 |
2013年 | 6817篇 |
2012年 | 4176篇 |
2011年 | 4268篇 |
2010年 | 3425篇 |
2009年 | 3037篇 |
2008年 | 2852篇 |
2007年 | 2910篇 |
2006年 | 2601篇 |
2005年 | 2336篇 |
2004年 | 1992篇 |
2003年 | 1824篇 |
2002年 | 1389篇 |
2001年 | 1333篇 |
2000年 | 1010篇 |
1999年 | 867篇 |
1998年 | 732篇 |
1997年 | 681篇 |
1996年 | 575篇 |
1995年 | 561篇 |
1994年 | 472篇 |
1993年 | 407篇 |
1992年 | 458篇 |
1991年 | 384篇 |
1990年 | 304篇 |
1989年 | 245篇 |
1988年 | 249篇 |
1987年 | 246篇 |
1986年 | 183篇 |
1985年 | 209篇 |
1984年 | 172篇 |
1983年 | 127篇 |
1982年 | 107篇 |
1981年 | 88篇 |
1980年 | 59篇 |
1979年 | 58篇 |
1978年 | 70篇 |
1977年 | 46篇 |
1976年 | 47篇 |
1975年 | 48篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
91.
92.
《Clínica e investigación en ginecología y obstetricia》2019,46(4):167-169
Gestational trophoblastic disease (GTD) is a group of tumours caused by the hyperproliferation of trophoblast cells and is noted for its overproduction of hCG. Among its manifestations, there may be hyperthyroidism, due to the stimulating activity of hCG on TSH receptors. In most cases it is only a biochemical hyperthyroidism, with its presentation as symptomatic hyperthyroidism being much less frequent. We report the case of a patient with GTD, who at diagnosis presented with symptomatic hyperthyroidism. Treatment included surgical evacuation of the hydatidiform mole, as well as a beta-blocker and antithyroid drug treatment to relieve the symptoms. 相似文献
93.
94.
Huiru Dong Kanna Hayashi Joel Singer Michael John Milloy Kora DeBeck Evan Wood Thomas Kerr 《Addiction (Abingdon, England)》2019,114(12):2173-2186
95.
96.
目的药品的生产场所是为满足药品生产要求的一系列生产要素的组合,其既是药品生产的硬件条件,也是注册申报时审评的物质基础。笔者旨在初步探讨我国化学药品申报资料中生产线的内涵、外延,以期为规范药品注册申报提供一定的参考。方法在梳理我国化学药品申报资料中关于生产场所信息的历次要求的基础上,结合日常药学审评工作以及具体案例进行分析。结果与结论应明确申报资料中拟定生产线的内涵及边界,强化不同监管部门之间的有效沟通,及时更新相关证明性信息,同时还应持续关注我国关于生产线相关变更的法律法规修订进展。 相似文献
97.
Viewing cancer as a large, evolving population of heterogeneous cells is a common perspective. Because genomic instability is one of the fundamental features of cancer, this intrinsic tendency of genomic variation leads to striking intratumor heterogeneity and functions during the process of cancer formation, development, metastasis, and relapse. With the increased mutation rate and abundant diversity of the gene pool, this heterogeneity leads to cancer evolution, which is the major obstacle in the clinical treatment of cancer. Cells rely on the integrity of DNA repair machineries to maintain genomic stability, but these machineries often do not function properly in cancer cells. The deficiency of DNA repair could contribute to the generation of cancer genomic instability, and ultimately promote cancer evolution. With the rapid advance of new technologies, such as single-cell sequencing in recent years, we have the opportunity to better understand the specific processes and mechanisms of cancer evolution, and its relationship with DNA repair. Here, we review recent findings on how DNA repair affects cancer evolution, and discuss how these mechanisms provide the basis for critical clinical challenges and therapeutic applications. 相似文献
98.
99.
《Clinical colorectal cancer》2020,19(4):285-290
BackgroundFOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with previously treated metastatic colorectal cancer (mCRC). Our aim was to investigate efficacy and tolerability of this combination in the first line.Patients and MethodsPatients with untreated documented mCRC received aflibercept plus FOLFIRI every 14 days until progression or unacceptable toxicity in an open, phase II single-arm, multicenter trial. The primary endpoint was the 6-month PFS rate. Secondary endpoints were OS and tolerability. A 2-step Simon design was used with H0: 55% and H1= 75%. Data were analyzed in intention to treat.ResultsForty-one patients were included, and 40 were analyzed (1 consent withdrawal) in 9 French centers between October 2014 and February 2017. The median age was 65 years (range, 46-81 years), 55% had ≥ 2 metastatic sites, and 50% and 15% had RAS and BRAF mutations, respectively. Twenty-two (54.5%; 95% confidence interval, 38.9%-68.5%) patients were alive and non-progressive at 6 months. FOLFIRI + aflibercept was considered ineffective, resulting in the cessation of inclusions. The median follow-up was 34 months. The overall response rate was 55%, and the disease control rate was 80%. The median duration of treatment was 5.3 months; the median PFS and OS were 8.2 and 18.6 months, respectively. Grade 3 to 4 adverse events were mainly gastrointestinal (47.5%) and vascular (32.5%). Of the patients, 87.5% had at least 1 dose modification.ConclusionAlthough the primary objective was not met, first-line FOLFIRI + aflibercept for mCRC leads to median PFS and OS close to those reported with classical doublet and targeted agents, but with significant toxicities needing dose reduction. 相似文献
100.
导师花宝金教授长期从事中西医结合肿瘤的临床与基础研究。认为"正气内虚"是肿瘤发生的根本,"癌毒"是肿瘤发生的必要条件。收集导师多年临床组方,归纳、总结后发现清热解毒或攻毒散结之法常贯穿于始终。结合现代药物理论及导师多年临床经验,总结出临床常用七组抗癌解毒药对:(1)夏枯草、半枝莲;(2)石见穿、猫爪草;(3)金荞麦、蒲公英;(4)龙葵、白英、白花蛇舌草;(5)山慈菇、浙贝母;(6)藤梨根、蛇莓;(7)全蝎、蜈蚣。通过整体与局部的辨病与辨证、根据肿瘤的不同类型及发病阶段,结合癌毒的病机特点,灵活运用抗癌解毒药对,临床疗效确切。 相似文献